Filing Flows › GeneDx Holdings (WGS) › Q2 2026 › vs Q1 2026
GeneDx Holdings (WGS) Q2 2026 vs Q1 2026 (quarter over quarter)
GeneDx Holdings's revenue rose $12.2M (+12%) from $102M in Q1 2026 to $114M in Q2 2026. The biggest changes: Diagnostic Test +$10.6M (+10%); Other revenue +$1.6M (+167%).
GeneDx Holdings, Q2 2026: revenue $114M (+11% year over year), operating margin -15.3%, net loss $17.7M, operating cash flow −$29.0M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Patients with third-party insurance | $94.7M | $84.9M | $9.8M | +12% |
| Institutional customers | $16.1M | $16.1M | $24K | +0.1% |
| Self-pay patients | $1.0M | $286K | $756K | +264% |
| Diagnostic Test | $112M | $101M | $10.6M | +10% |
| Other revenue | $2.6M | $955K | $1.6M | +167% |
| Revenue | $114M | $102M | $12.2M | +12% |
| Income tax benefit | $518K | −$897K | $1.4M | — |
| Net loss | $17.7M | $63.3M | −$45.6M | -72% |
| Costs & expenses | $133M | $166M | −$32.9M | -20% |
| Operating costs | $132M | $160M | −$27.8M | -17% |
| Interest & other, net | $803K | $4.9M | −$4.1M | -84% |
| Cost of revenue | $36.2M | $34.0M | $2.2M | +6% |
| Research & development | $19.7M | $19.8M | −$148K | -0.7% |
| SG&A | $76.0M | $74.6M | $1.4M | +2% |
| Operating cash sources | $42.0M | $48.2M | −$6.2M | -13% |
| Depreciation & amortization | $6.7M | $6.8M | −$95K | -1% |
| Share-based compensation | $6.3M | $9.0M | −$2.7M | -30% |
| Cash used in operations | $29.0M | $32.4M | −$3.4M | -11% |
| Net loss absorbed | $17.7M | $63.3M | −$45.6M | -72% |
| Working capital & other | $24.3M | −$15.1M | $39.4M | — |
Questions
How much did GeneDx Holdings's revenue grow quarter over quarter in Q2 2026?
GeneDx Holdings's revenue rose $12.2M (+12%) from $102M in Q1 2026 to $114M in Q2 2026.
What drove GeneDx Holdings's revenue change in Q2 2026?
Diagnostic Test +$10.6M (+10%); Other revenue +$1.6M (+167%).